Cover Image

Drug-coated balloons in below-the-knee arteries: analysis of a real-world data set

Summary:Background: The search for an optimal interventional treatment strategy in infrapopliteal peripheral artery disease remains in the focus of interest. Whether drug-coated balloons (DCB) might enhance interventional outcomes after crural interventions is a matter of debate, as studies yielded...

Full description

Saved in:
Bibliographic Details
Main Authors: Stoll, Felicitas E. (Author) , Uslu, Reyhan (Author) , Blessing, Erwin (Author) , Frey, Norbert (Author) , Katus, Hugo (Author) , Erbel, Christian (Author) , Heilmeier, Britta (Author) , Müller, Oliver J. (Author)
Format: Article (Journal)
Language:English
Published: May 23, 2022
In: Vasa
Year: 2022, Volume: 51, Issue: 4, Pages: 256-262
ISSN:1664-2872
DOI:10.1024/0301-1526/a001009
Online Access:lizenzpflichtig
lizenzpflichtig
Get full text
Author Notes:Felicitas Stoll, Reyhan Uslu, Erwin Blessing, Norbert Frey, Hugo A. Katus, Christian Erbel, Britta Heilmeier and Oliver J. Müller
Description
Summary:Summary:Background: The search for an optimal interventional treatment strategy in infrapopliteal peripheral artery disease remains in the focus of interest. Whether drug-coated balloons (DCB) might enhance interventional outcomes after crural interventions is a matter of debate, as studies yielded conflicting results on DCB safety and efficacy. Patients and methods: We analyzed a retrospective cohort of 75 infrapopliteal DCB interventions performed at our institution in 68 patients with peripheral artery disease in Rutherford category 3 to 6. Results: Despite a high rate of long complex lesions and multi-vessel disease, freedom from clinically driven target lesions revascularization (TLR) after 365 days was 68%. After six months, healing or significant improvement of the ischemic ulcer was observed in 78% of cases. Accordingly, freedom from major amputation and death after 365 days was 82%. Freedom from major amputation and death was 76.2% of cases in patients with diabetes mellitus as opposed to 91.5% in patients without diabetes mellitus (p=0.049). Conclusions: With this real-world analysis we would like to contribute to the ongoing discussion on the benefit and safety of DCB treatment in below-the-knee interventions.
Item Description:Gesehen am 27.02.2023
Physical Description:Online Resource
ISSN:1664-2872
DOI:10.1024/0301-1526/a001009

Similar Items